Welcome to our dedicated page for Bioadaptives news (Ticker: BDPTD), a resource for investors and traders seeking the latest updates and insights on Bioadaptives stock.
BioAdaptives, Inc. (BDPTD) generates a steady flow of news centered on science-based wellness, nootropic innovation, stem cell–support technologies, and pet health solutions. Recent announcements describe product launches, clinical trial milestones, third-party certifications, and leadership appointments that shape the company’s direction in human and animal wellness.
Among its headline developments, BioAdaptives has announced the commercial launch of MyndMed™, a cognitive-support dietary supplement formulated to support memory, focus, mental clarity, and overall brain performance. News coverage also details TruShield™ Laboratory Services’ certification of MyndMed™ as free from World Anti-Doping Agency (WADA)–prohibited substances, a key point for athletes and organizations such as the Ultimate Fighting Championship® (UFC) that operate under strict anti-doping rules.
Other news items highlight the national launch plans for NeuroRush™, an adaptogenic nootropic combining ingredients such as Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng, and Mucuna Pruriens, as well as the rollout of Pawpa™ Regen and Regen Dog Chews through the PawPa™ pet wellness division. Company updates describe veterinarian trials, the APBAR® rating system for tracking canine health improvements, and reported gains in stem cell activity and pet vitality.
Coverage also includes the introduction of Xcellara™ Stem Cell Activator, dosage trial results for the Zeranovia™ weight loss product, the appointment of experienced leaders such as Reed Harris and Mark Frissora, and a FINRA-approved dividend for common stock shareholders. Visitors to this news page can review these announcements to understand how BioAdaptives presents its product pipeline, scientific claims, quality measures, and corporate governance developments over time.
BioAdaptives (OTC: BDPT) announced the commercial launch of MyndMed™, a cognitive-support dietary supplement available online as of October 7, 2025.
The company said MyndMed™ combines well-studied nutrients targeting cholinergic tone, neuronal energy metabolism, antioxidant defenses, and neuroplasticity, and that manufacturing occurs in cGMP-certified U.S. facilities with third‑party testing and transparent labeling. BioAdaptives is scaling production to meet expected high order volumes beginning in November and offers nationwide U.S. shipping, introductory promotions, and subscription options at www.MyndMed.com.
BioAdaptives (OTCMKTS: BDPTD) announced that its nootropic supplement MyndMed™ has received full clearance from TruShield™ Laboratory Services, confirming compliance with World Anti-Doping Agency (WADA) and Ultimate Fighting Championship (UFC) standards.
The comprehensive testing verified that MyndMed™, which combines botanical extracts, amino acids, and neuro-support nutrients, contains no banned or prohibited substances. This certification enables UFC athletes to use the supplement without concerns about anti-doping violations.
The product is designed to enhance focus, reaction time, and cognitive performance while supporting neurotransmitter balance and neural resilience for athletes under high-stress competition conditions.
BioAdaptives (OTC:BDPTD) announced the national launch of NeuroRush™, a next-generation nootropic supplement, scheduled for commercial release in August/September 2025. The product combines six clinically studied ingredients including Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng, and Mucuna Pruriens.
The supplement will be available in two formulations: one with natural caffeine and a caffeine-free version. Following successful test market results, the company plans to distribute NeuroRush™ through online retailers, direct-to-consumer channels, and health & wellness partners nationwide.
BioAdaptives (OTC Pink: BDPTD) announced the nationwide launch of Pawpa™ Regen, a revolutionary canine supplement designed to promote regenerative healing through stem cell activation in aging dogs. Following a successful limited market release, the product will be available nationwide through e-commerce platforms by late July 2025.
The proprietary formula works by stimulating the release of circulating stem cells, leading to improvements in vitality, mobility, and overall wellness in older dogs. Early testing has shown positive results in energy levels, coat health, mobility, and temperament. The company is scaling production to meet anticipated strong demand in the pet wellness market.
BioAdaptives Inc. (OTC: BDPT) has announced successful completion of dosage trials for its weight loss product Zeranovia™. The trial demonstrated significant results, with participants experiencing weight loss of 5-7 pounds per week with minimal side effects.
Key findings include consistent weight loss across participants, with the main side effect being mild gastrointestinal discomfort, manageable through increased water intake or dosage adjustments. All trial subjects requested to proceed to the next phase, demonstrating high satisfaction levels.
Based on these promising results, BioAdaptives is proceeding with dosage adjustments for the next stage of clinical trials, aiming to address the global need for effective and safe weight loss solutions.
BioAdaptives Inc. (OTC: BDPT) has appointed Reed Harris to its Board of Advisors. Harris, currently serving as Senior Vice President of Athlete Development and Marketing at UFC, brings over 40 years of experience in leadership and business management. He is the founder of World Extreme Cagefighting (WEC), which he sold to UFC in 2006 and managed until its 2012 merger.
Harris will collaborate with BioAdaptives' marketing department to launch several new products, including Xcellera, a stem cell activator. Clinical trials have shown Xcellera increases circulating stem cells by 268.8% in 28 days, supporting tissue repair, anti-aging, immune and cardiovascular functions.
BioAdaptives Inc (OTC: BDPT) has appointed Mark Frissora to its Board of Directors. Frissora brings over 40 years of executive leadership experience, notably as Chairman and CEO of Hertz Global Holdings, where he led a comprehensive revitalization that positioned Hertz as the world's fastest rental car company.
At Caesars Entertainment, Frissora orchestrated a global brand relaunch, strengthening the company's position in the gaming industry. His earlier career included roles at General Electric and North American Philips, where he developed expertise in marketing, brand development, and corporate strategy.
BioAdaptives' CEO James Keener expressed confidence that Frissora's experience in transformative leadership and operational excellence will help advance the company's mission of delivering innovative health and wellness solutions.
BioAdaptives Inc. (OTC: BDPT) has received FINRA approval for a dividend distribution to common stock shareholders. The dividend will be payable on January 22, 2025, with an Ex-dividend Date of January 23, 2025. The distribution excludes preferred stockholders.
Shareholders holding stock in certificate or book entry form with the transfer agent will receive confirmation letters for their new stock issuance in book entry form. CEO James Keener expressed gratitude to shareholders for their support and confidence in the company's vision to revolutionize health and wellness. The company continues to focus on developing innovative health solutions and expanding its market presence both domestically and internationally.
BioAdaptives (OTC: BDPT) has launched Xcellara™ Stem Cell Activator, a new supplement designed to enhance stem cell regeneration through a blend of adaptogens, herbs, and beneficial bacteria. The product has been scientifically shown to increase circulating stem cells in humans and animals.
The supplement provides approximately 6 grams of complete protein per 10 grams and is rich in vitamins A, C, E, B-complex, and 62 essential minerals. Key benefits include cardiovascular support, cholesterol management, anti-inflammatory properties, and metabolic health enhancement. The product undergoes rigorous laboratory testing to ensure quality.
FAQ
What is the current stock price of Bioadaptives (BDPTD)?
What is the market cap of Bioadaptives (BDPTD)?
